Resivant Medical Taps Jeff Clark as a Strategic Addition to its Board

AKRON, Ohio, March 26, 2025 /PRNewswire/ -- Resivant Medical today announced that Jeff Clark, a longtime leader in the medical device industry, was elected to its Board of Directors by the company's shareholders.

"We are extremely pleased to welcome Jeff to our board," said Resivant Medical Board Chairman Russ Donda. "Jeff's 30+ years of experience as a leader in surgical adhesive and medical device development and commercialization will be invaluable as we continue to execute our mission to bring the game-changing Cutiva™ adhesive platform to market to help patients in the U.S. and beyond."

Mr. Clark served as CEO of HyperBranch Medical Technology where he led the development of Adherus AutoSpray Dural Sealant which was successfully commercialized worldwide and later acquired by Stryker Corp in 2018. Earlier in his career, Mr. Clark was vice president of research and development at Closure Medical Corporation, where he led the development of the Dermabond topical skin adhesive. This was the first topical skin adhesive approved by the U.S. Food and Drug Administration (FDA), and the company was acquired by Ethicon, a Johnson & Johnson Company.

About Resivant Medical:

Resivant Medical, a pioneer in the field of medical adhesives, has developed groundbreaking adhesive technology that enhances usability and performance for both patients and healthcare professionals. Its range of skin closure adhesive products is designed for topical application on wounds and surgical incisions. Resivant has received U.S. FDA 510(k) clearance for its first two products, Cutiva™ Topical Skin Adhesive, and Cutiva PLUS™ Skin Closure System. The global skin closure market, encompassing both traditional and advanced surgical closure methods, was valued at approximately USD $14.4 billion in 2024 and is anticipated to experience significant growth in the coming years.

For more information, visit www.resivant.com
Email: [email protected]
Media inquiries: Kelly Arledge, +1.614.205.0339

SOURCE Resivant Medical